ZygoFix
- Industry
- Medical Devices
- Founded Year
- 2017
- Headquarters
- Misgav, Israel
- Employee Count
- 4
Key People
-
Ofer Levy - Chief Executive Officer
Email: ofer@zygofix.com
- Uri Arnin - Founder & Chief Technology Officer
- Yizhar Floman - Co-Founder & Medical Director
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced MedTech entrepreneurs with a proven track record.
ZygoFix was founded by Prof. Yizhar Floman and Uri Arnin, who previously co-founded ApiFix, a company acquired by OrthoPediatrics in 2020. Their prior success in the spinal implant sector demonstrates their capability to develop and commercialize innovative medical devices.
- Clinical Need
-
Aspect: Very Strong
Summary: The zLOCK system addresses a significant unmet need in spinal fusion procedures.
Traditional spinal fusion surgeries often involve complex procedures with significant risks. ZygoFix's zLOCK system provides a less invasive solution, potentially reducing surgical complications and recovery times, thereby addressing a critical need in the market.
- Competition
-
Aspect: Somewhat crowded
Summary: The spinal fusion market has several established players, but ZygoFix's unique approach differentiates it.
The spinal fusion device market includes numerous companies offering various solutions. However, ZygoFix's screwless, minimally invasive implant sets it apart, potentially capturing market share from traditional methods.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves moderate complexity with predictable development pathways.
ZygoFix's zLOCK system leverages 3D printing technology to create implants that conform to the patient's anatomy. This approach utilizes existing technologies in a novel application, reducing technical uncertainties.
- Patent
-
Aspect: Strong
Summary: ZygoFix holds multiple patents protecting its innovative spinal fusion technology.
ZygoFix has secured patents for its zLOCK implant and delivery system, ensuring protection against competitors and reinforcing its market position.
- Financing
-
Aspect: Medium
Summary: The company has secured funding from reputable investors but may require additional capital for expansion.
ZygoFix has raised funds from investors like The Trendlines Group and the Israel Innovation Authority. However, to achieve significant market share, additional financing will be essential for manufacturing, marketing, and distribution efforts.
- Regulatory
-
Aspect: 510k/PMA
Summary: The zLOCK system has received CE Mark and FDA clearance, facilitating market entry.
Obtaining CE Mark in 2021 and FDA clearance in 2024 demonstrates the safety and efficacy of the zLOCK system, enabling ZygoFix to market its product in Europe and the United States.
Opportunity Rollup
- Odds of Success
- 3.65
- Peak Market Share
- 4.9
- Segment CAGR
- 3.0%
- Market Segment
- Orthopedic Devices
- Market Sub Segment
- Spinal Fusion Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.71 |
| 4 | 3.43 |
| 5 | 4.90 |
Key Takeaway
ZygoFix's innovative zLOCK system addresses a significant clinical need with a minimally invasive approach, supported by experienced leadership and strong intellectual property, positioning the company for moderate success in the competitive spinal fusion market.